Abstract: Electrochemiluminescent moieties having the formula(Re(P).sub.m (L.sup.1).sub.n (L.sup.2).sub.o (L.sup.3).sub.p (L.sup.4).sub.t (B).sub.uwhereinP is a polydentate ligand of Re;L.sup.1, L.sup.2, L.sup.3 and L.sup.4 are ligands of Re, each of which may be the same as or not the same as each other ligand;B is a substance which is a ligand of Re or is conjugated to one or more of P, L.sup.1, L.sup.2, L.sup.3 and L.sup.4 ;m is an integer equal to or greater than 1;each of n, o, p, q, r and s is zero or an integer;t is an integer equal to or greater than 1; andu is an integer equal to or greater than 1;P, L.sup.1, L.sup.2, L.sup.3, L.sup.4 and B being of such composition and number that the chemical moiety can be induced to electrochemiluminesce and the total number of bonds to Re provided by the ligands of Re being equal to the coordination number of Re are disclosed.

Abstract: An interaction system, including an antibody or, antibody fragment having functional capability, which comprises a surfactant-stabilized microheterogeneous dispersion of aqueous phase in a water-immiscible medium, said aqueous phase containing an amount of said antibody or said fragment in a functional state sufficient to effect the interaction; and methods for making and for using said system.

Abstract: Catalytic antibody components, methods for producing catalytic antibody components, methods for using catalytic antibody components, in particular, single chain and smaller components are disclosed. Catalytic antibody components able to promote the cleavage or formation of an amide, peptide, ester or glycosidic bond, and which are prepared from monoclonal catalytic antibodies, catalytic autoantibodies or by site-directed mutagenesis are disclosed. Methods of using catalytic antibody components alone or in combination with other antibody components or other biological moieties are disclosed.

Abstract: A method for treating human disease of viral etiology which employs the administration of a pharmaceutically effective amount of a live attenuated virus. Avian paramyxovirus is the virus preferred for use in live attenuated vaccine form, although other viruses of human and nonhuman origin have also been shown to be effective. The administration of a pharmaceutically effective amount of avian paramyxovirus and avian rotavirus vaccine has been shown to be efficacious in the treatment of Herpes virus infections, hepatitis, some cancers, aphthous stomatitis, acquired immune deficiency syndrome (AIDS) and polyarteritis nodosa.

Abstract: Specific, selective inhibitors of catalytic antibodies both synthetic and naturally occurring, their use and compositions thereof are disclosed. In particular, an inhibitor preventing the hydrolysis of the peptide bond between amino acid residues 16 and 17 in the neurotransmitter vasoactive intestinal peptide (VIP) by an anti-VIP catalytic autoantibody is disclosed.

Abstract: A method for increasing the rate of chemical reactions involving the conversion of at least one reactant to at least one product involves contacting the reactant with an appropriate monoclonal antibody under conditions permitting the formulation of a complex between the antibody and the reactant. The complexed reactant is converted to the product which is then released from the complex. The monoclonal antibody may employ a cofactor and may be directed to a known substrate of an enzyme. Methods for preparing such monoclonal antibodies are also disclosed.

Abstract: A method for treating human disease of viral etiology which employs the administration of a pharmaceutically effective amount of a live attenuated virus. Avian paramyxovirus is the virus preferred for use in live attenuated vaccine form, although other viruses of human and nonhuman origin have also been shown to be effective. The administration of a pharmaceutically effective amount of avian paramyxovirus and avian rotavirus vacciine has been shown to be efficacious in the treatment of Herpes virus infections, hepatitis-A, some cancers, aphthous stomatitis, acquired immune deficiency syndrome (AIDS) and polyarteritis nodosa.

Abstract: A method for increasing the rate of chemical reactions involving the conversion of at least one reactant to at least one product involves contacting the reactant with an appropriate monoclonal antibody under conditions permitting the formation of a complex between the antibody and the reactant. The complexed reactant is converted to the product which is then released from the complex. The monoclonal antibody may employ a cofactor and may be directed to a known substrate of an enzyme. Methods for preparing such monoclonal antibodies are also disclosed.

Abstract: A method for increasing the rate of chemical reactions involving the conversion of at least one reactant to at least one product involves contacting the reactant with an appropriate monoclonal antibody under conditions permitting the formation of a complex between the antibody and the reactant. The complexed reactant is converted to the product which is then released from the complex. The monoclonal antibody may employ a cofactor and may be directed to a known substrate of an enzyme. Methods for preparing such monoclonal antibodies are also disclosed.